Annual zoledronic acid did not increase renal abnormalities at 2 years in postmenopausal women with osteoporosis

Molony, Donald A.
December 2008
ACP Journal Club;12/16/2008, Vol. 149 Issue 6, p6
Academic Journal
The article discusses a medical research related to increase in renal abnormalities due to annual zoledronic acid in postmenopausal women with osteoporosis. Several postmenopausal women in the age group of 65 to 89 years were examined at 239 centers in 27 countries. It was concluded that infusions of zoledronic acid in postmenopausal women with osteoporosis did not increase renal abnormalities at two years.


Related Articles

  • Bisphosphonates and Chronic Kidney Disease. Andersen, Matthew; Kukreja, Subhash // Kidney;May/Jun2008, Vol. 17 Issue 3, p119 

    The article presents a medical study on the pathogenesis of chronic kidney disease (CKD) and the effectiveness of bisphosphonates. It discusses the association of bone disease, renal osteodystrophy (ROD), and postmenopausal osteoporosis (PMO) to CKD population. The medication of biphosphonates...

  • Pilsicainide interaction.  // Reactions Weekly;4/29/2006, Issue 1099, p15 

    Reports on the development of arrhythmia in a 72-year-old woman who had chronic renal impairment and was receiving pilsicainide during concomitant treatment with cetirizine. Dosage of oral pilsicainide taken by the patient per day; Hospitalization of the woman for lumbar herniation; Complaint...

  • Pharmacokinetics of Oral Recombinant Human Parathyroid Hormone [rhPTH(1-31)NH] in Postmenopausal Women with Osteoporosis. Sturmer, Amy; Mehta, Nozer; Giacchi, Jenna; Cagatay, Tulin; Tavakkol, Roxanne; Mitta, Sheela; Fitzpatrick, Lorraine; Wald, Jeff; Trang, John; Stern, William // Clinical Pharmacokinetics;2013, Vol. 52 Issue 11, p995 

    Background and Objectives: Teriparatide [rhPTH(1-34)OH] is a subcutaneously administered bone anabolic drug that increases bone mineral density (BMD) and reduces the risk of osteoporotic fracture. Because rhPTH(1-34)OH is administered by injection, oral delivery is a desirable alternative....

  • Impact of Impaired Renal Function on the Pharmacokinetics of the Antiepileptic Drug Lacosamide. Cawello, Willi; Fuhr, Uwe; Hering, Ursula; Maatouk, Haidar; Halabi, Atef // Clinical Pharmacokinetics;2013, Vol. 52 Issue 10, p897 

    Background and Objective: The antiepileptic drug lacosamide is eliminated predominantly via the kidneys. Therefore, an evaluation of the impact of renal impairment on its pharmacokinetic profile is an important component of its safety assessment. The objective of this study was to evaluate the...

  • Laparoscopic Transperitoneal Heminephrectomy for Duplex Kidney in Infants and Children: A Comparative Study. Dingemann, Carmen; Petersen, Claus; Kuebler, Joachim F.; Ure, Benno M.; Lacher, Martin // Journal of Laparoendoscopic & Advanced Surgical Techniques;Oct2013, Vol. 23 Issue 10, p889 

    Background and Objective: Evaluation of the feasibility, safety, and outcome of laparoscopic heminephrectomy for duplex kidneys in children above and below the age of 12 months. Patients and Methods: The transperitoneal surgical technique included division of the parenchyma with a sealing device...

  • Survival of Patients Treated with Online Hemodiafiltration Compared to Conventional Hemodialysis. Mesaroš-Devčić, Iva; Tomljanović1, Irena; Mikolašević, Ivana; Dvornik, Štefica; Vujičić, Božidar; Pavletić-Peršić, Martina; Rački, Sanjin // Collegium Antropologicum;Sep2013, Vol. 37 Issue 3, p827 

    Accumulating data from observational studies showed that online hemodiafiltration (OLHDF) might improve survival in chronic hemodialysis (HD) patients. According to this data, the aim of our study was to investigate whether there was a difference in survival of patients treated with OLHDF...

  • ACTONE OFFERED FOR PREVENTION/TREATMENT OF OSTEOPOROSIS.  // Worldwide Biotech;Oct2000, Vol. 12 Issue 10, p5 

    Introduces Actonel, a treatment and prevention drug for postmenopausal osteoporosis from Procter & Gamble Pharmaceuticals Canada Inc. and Aventis Pharma Incorporated.

  • Antiestrogenic action of raloxifene and tamoxifen: Today and tomorrow.  // JNCI: Journal of the National Cancer Institute;07/01/98, Vol. 90 Issue 13, p967 

    Discusses the availability of raloxifene to physicians as a bone maintenance therapy to prevent osteoporosis in postmenopausal women. Original name given to raloxifene; In-depth look at raloxifene; Antiestrogenic action of raloxifene; Reference to the estrogen drug tamoxifen; Difference between...

  • Thousands of patients get costly, useless treatments, says report. Winestock, Geoff // Australian Financial Review (0404-2018);8/20/2015, p3 

    The article focuses on questionable care: avoiding ineffective treatments, a report issued by the Grattan Institute in which it analyzed that majority expensive treatment services given to patients in a year is useless as cheap alternatives for the treatment are available in the market.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics